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Background: The structure and the physiological function(s) of vitamin K epoxide reductase complex subunit 1-like 1
(VKORC1L1) are unknown.
Results: VKORC1L1 has four transmembrane domains and employs an intra-molecular electron transfer pathway for active site
regeneration.
Conclusion: The different structure and reaction mechanism of VKORC1L1, as compared with VKORC1, suggest that
VKORC1L1 has different physiological function(s).
Significance: Four conserved cysteines in VKORC1L1 function in concert for active site reduction.
Vitamin K epoxide reductase complex subunit 1 (VKORC1)
reduces vitamin K epoxide in the vitamin K cycle for post-transla-
tional modification of proteins that are involved in a variety of
biological functions. However, the physiological function of
VKORC1-like 1 (VKORC1L1), a paralogous enzyme sharing about
50% protein identity with VKORC1, is unknown. Here we deter-
mined the structural and functional differences of these two
enzymes using fluorescence protease protection (FPP) assay and an
in vivo cell-based activity assay. We show that in vivo VKORC1L1
reduces vitamin K epoxide to support vitamin K-dependent car-
boxylation as efficiently as does VKORC1. However, FPP assays
show that unlike VKORC1, VKORC1L1 is a four-transmembrane
domain protein with both its termini located in the cytoplasm.
Moreover, the conserved loop cysteines, which are not required for
VKORC1 activity, are essential for VKORC1L1’s active site regen-
eration. Results from domain exchanges between VKORC1L1 and
VKORC1 suggest that it is VKORC1L1’s overall structure that
uniquely allows for active site regeneration by the conserved loop
cysteines. Intermediate disulfide trapping results confirmed an
intra-molecular electron transfer pathway for VKORC1L1’s active
site reduction. Our results allow us to propose a concerted action of
the four conserved cysteines of VKORC1L1 for active site regener-
ation; the second loop cysteine, Cys-58, attacks the active site disul-
fide, forming an intermediate disulfide with Cys-139; the first loop
cysteine, Cys-50, attacks the intermediate disulfide resulting in
active site reduction. The different membrane topologies and reac-
tion mechanisms between VKORC1L1 and VKORC1 suggest that
these two proteins might have different physiological functions.
Vitamin K epoxide reductase complex subunit 1 (VKORC1)2 is
a polytopic membrane protein of the endoplasmic reticulum (ER)
(1, 2). It is responsible for the reduction of vitamin K 2,3-epoxide
(KO, a quinone epoxide) to vitamin K (a quinone), and can also
reduce vitamin K to vitamin K hydroquinone (KH2). This series of
quinone reductase reactions is an essential part of a redox cycle
known as the vitamin K cycle (3). The active form of the vitamin in
the cycle, KH2, is a cofactor for -glutamyl carboxylase, which cat-
alyzes post-translational modification of vitamin K-dependent
proteins essential for blood coagulation, bone homeostasis, vascu-
lar mineralization, signal transduction, and cell proliferation
(4–7).
VKORC1 is the target of warfarin, the most commonly pre-
scribed oral anticoagulant used for prevention and treatment of
thrombosis (8). Warfarin exerts its effect by inhibition of
VKORC1 activity, which reduces the availability of KH2 and
impairs the synthesis of functional clotting factors. Finding the
appropriate dosage of warfarin required to achieve stable anti-
coagulation has been a challenge, because of its narrow therapeu-
tic index and broad individual variability (9). Since the identifica-
tion of the VKORC1 gene (1, 2), single nucleotide polymorphisms
have been found in the coding as well as non-coding regions of
VKORC1 in warfarin-resistant/sensitive patients. These genetic
variations have been successfully used as a marker for managing
warfarin maintenance dosage (10, 11).
Site-directed mutagenesis studies show that VKORC1 uses a
CXXC redox motif as its active site (12–14). Membrane topol-
ogy studies suggest that VKORC1’s active site is located at the
N-terminal of the last transmembrane domain (TMD) facing
the ER lumen (15, 16). During the reduction of KO or vitamin K,
VKORC1’s active site cysteines (Cys-132 and Cys-135) are oxi-
dized to a disulfide bond that must be reduced to free cysteines
to reactivate the enzyme. Thioredoxin was proposed as the
physiological reductant for VKORC1’s active site regeneration
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(17–20); however, this hypothesis has been questioned (21).
Currently, the physiological reductant of VKORC1 is unknown.
VKORC1 appears to be a member of a large family of homo-
logues (VKORHs) widely distributed among vertebrates,
invertebrates, plants, bacteria, and archaea (22). In bacteria,
VKORHs are present only in strains lacking DsbB, a cytoplas-
mic membrane protein that is important for protein oxidative
folding in the periplasm (23). Bacterial VKORHs can function-
ally complement Escherichia coli strains that lacking DsbB to
restore protein-disulfide formation (23, 24). It has been shown
that the conserved loop cysteines in bacterial VKORHs shuttle
electrons to the disulfide-bonded CXXC active site through an
intra-molecular electron transfer pathway, similar to that of
DsbB (25, 26). This mechanism has been extended to human
VKORC1 (26 –28). However, our recent study shows that the
intra-molecular electron transfer pathway for active site regen-
eration does not apply to human VKORC1 (15).
When the VKORC1 gene was identified, homologous searches
with VKORC1 detected a paralogous protein, VKORC1L1 (1).
Although the structure-function relationships of VKORC1 have
been extensively studied (29), functional studies of VKORC1L1
have been reported only recently (30, 31). Unlike VKORC1, sin-
gle-nucleotide polymorphisms of the VKORC1L1 gene appear
not to be directly associated with the warfarin maintenance
dosage (32). In addition, results from an in vitro study suggest
that VKORC1L1 functions as a housekeeping protein that helps
to prevent intracellular oxidative damage (31). Therefore, it has
been proposed that VKORC1L1 is not involved in the vitamin K
cycle (31). On the other hand, a more recent study suggests that
VKORC1L1 might rescue VKORC1 activity in extrahepatic tis-
sues during anticoagulation therapy (30). Moreover, our results
suggest that VKORC1L1 can support vitamin K-dependent
carboxylation as efficiently as does VKORC1 (33). However, it
appears unlikely that VKORC1L1 plays a key role in the vitamin
K cycle under physiological conditions (33, 34). If it were, the
murine knock-out of VKORC1 would be viable (34), and no
significant decrease of KO reductase activity in the VKORC1
knock-out cells would have been observed (33). Therefore,
despite the high homology of VKORC1L1 and VKORC1, the
physiological function of VKORC1L1 is still unclear.
To better understand the structure-function relationships
that define VKORC1L1 activity, we report here: 1) the mem-
brane topology of VKORC1L1, determined using a fluores-
cence protease protection (FPP) assay in live mammalian cells;
2) the role of VKORC1L1’s conserved loop cysteines in KO
reduction, using our recently established cell-based activity
assay (35); 3) a possible mechanism for VKORC1L1’s active site
regeneration by the conserved loop cysteines. Our results show
that VKORC1L1 has a different membrane topology and reac-
tion mechanism than that of VKORC1.
EXPERIMENTAL PROCEDURES
Materials—Vitamin K1, warfarin, digitonin, and trypsin
(bovine pancreas) were obtained from Sigma-Aldrich. Vitamin
K epoxide was prepared as described previously (36). Vitamin
K1 (10 mg/ml) for cell culture was from Abbott Laboratories
(Lake Forest, IL). Methoxy-polyethylene glycol maleimide,
molecular weight 5000 (mPEG-MAL-5000), was purchased
from Nektar (Huntsville, AL). Slide-A-Lyzer MINI dialysis
unites (2K MWCO) were from Pierce Biotechnology, Inc.
Complete protease inhibitor mixture tablets were from Roche
(Indianapolis, IN). Xfect transfection reagent was from Clon-
tech Laboratories, Inc. (Mountain View, CA). Mammalian
expression vector pBudCE4.1, baculovirus expression vector
pFastBac I, and all cell culture mediums and oligonucleotide
primers were from Invitrogen Corp. (San Diego, CA). HEK293
cell line was from ATCC (Manassas, VA). The Sf9 (Spodoptera
frugiperda) cells were obtained from the Lineberger Cancer
Center at the University of North Carolina-Chapel Hill. Quick-
Change site-directed mutagenesis kits were from Agilent Tech-
nologies (Santa Clara, CA). Mouse anti-carboxylated FIX gla
domain monoclonal antibody was a gift from GlaxoSmithKline
(Philadelphia, PA) and Green Mountain Antibodies (Burling-
ton, VT). Anti-HA monoclonal antibody was from Covance
Inc. (Princeton, NJ). Horseradish peroxidase conjugated sheep
anti-human Protein C IgG and goat anti-mouse IgG were from
Affinity Biologicals, Inc. (Ancaster, ON, Canada) and Jackson
ImmunoResearch Laboratories, Inc. (West Grove, PA).
DNA Manipulations and Plasmid Constructions—Mamma-
lian expression vector pBudCE4.1 that independently expresses
two genes from a single vector was used for expressing
VKORC1, VKORC1L1, or their variants in HEK293 cells.
Metridia luciferase cDNA was cloned into one of the multi-
cloning sites of pBudCE4.1 as an internal control for the cell-
based activity assay; VKORC1 or VKORC1L1 constructs were
cloned into the other multi-cloning site as described previously
(15). All the VKORC1 or VKORC1L1 constructs contain a war-
farin-resistant mutation of Y139F or Y146F, respectively. Site-
directed mutagenesis was performed by a QuickChange
mutagenesis kit to create cysteine mutations in VKORC1L1
according to the manufacturer’s instructions. Replacement of
VKORC1L1’s conserved cysteine loop region or active site
sequences with that of VKORC1 was performed by overlap
PCR. For Western blot detection, an HA tag (YPYDVPDYA)
was introduced at the C terminus of the VKORC1 or
VKORC1L1. GFP fusions of the VKORC1 or VKORC1L1 used
in the FPP assays were constructed as described previously (15).
For the in vitro activity assay, VKORC1L1 and its cysteine
mutants were cloned into pFastBac I for expression in insect
cells. The nucleotide sequences of all the constructs were veri-
fied by sequencing at Eton Bioscience Inc. (RTP, NC).
FPP Assay—The FPP assay was performed as described pre-
viously (15). Briefly, HEK293 cells were subcultured into cham-
bered coverglass and transiently transfected with pBudCE4.1
plasmid DNA containing the GFP-tagged VKORC1 or
VKORC1L1. Forty-eight hours post-transfection, cells were
washed three times with KHM buffer (110 mM potassium acetate,
2 mM MgCl2, and 20 mM HEPES pH 7.2) and 200 l of KHM buffer
was added to each chamber before placing on the microscope
stage. Confocal microscopy was performed on a Zeiss LSM710
confocal laser scanning microscope (Carl Zeiss Microimaging,
Thornwood, NY). Images were collected using a 40/1.2NA
C-Apochromat objective lens. Visualization of the GFP was
achieved by use of a 488 nm Argon laser line for excitation, and
the detector was set to collect emissions at 493–530 nm. We
collected a time series of images of the chosen cell using ZEN
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software. Successive images were collected at an interval of 30 s.
Trypsin was added to the chamber 2 min after the addition of
digitonin at a final concentration of 2 M to elicit protease
digestion of GFP tag in the cytoplasm.
In Vivo and in Vitro VKORC1 and VKORC1L1 Activity
Assays—The in vivo activity assay for VKORC1, VKORC1L1,
and their variants used in this study were performed according
to our recently established cell-based activity assay (35). It is
based on the ability of VKORC1 (Y139F warfarin-resistant
mutant) or VKORC1L1 (Y146F warfarin-resistant mutant) to
convert sufficient KO to vitamin K in the native milieu
(HEK293 cells) to support the carboxylation of a chimera
reporter protein FIXgla-PC. Endogenous KO reductase activity
in HEK293 cells was inhibited by warfarin. Therefore, wild-type
VKORC1 and VKORC1L1 activity in this study refers to the
activity of warfarin-resistant mutants of VKORC1-Y139F and
VKORC1L1-Y146F, respectively. VKORC1L1, VKORC1, and
their variants were transiently expressed in FIXgla-PC/HEK293
cells. Metridia luciferase was coexpressed as the internal con-
trol from the same expression vector, pBudCE4.1. Transfected
cells were cultured in complete medium containing 5 M KO
with 2 M warfarin. Forty-eight hours post-transfection, car-
boxylated FIXgla-PC in the cell culture medium was measured
by ELISA. Typically, cells transfected with VKORC1L1 produce
150 ng/ml carboxylated FIXgla-PC in the culture medium.
Mock-transfected cells produce 5 ng/ml carboxylated
reporter protein. Luciferase activity was determined by inject-
ing 100 l of coelenterazine solution (1 M in PBS with 300 mM
NaCl) to 10 l of cell culture medium. Luminescence emission
(relative light units (RLU)) from the mixture was recorded at
480 nm with a delay of 6 s and integration time of 1 s.
VKORC1L1 activity was expressed as normalized carboxylated
FIXgla-PC (ng/ml/RLU). Wild-type VKORC1L1 activity was
normalized to 100%.
For the in vitro activity assay, VKORC1L1 or its cysteine
mutants were expressed in Sf9 cells. The conversion of KO to
vitamin K was determined by the traditional DTT-driven activ-
ity assay as described previously (2, 35).
Differential Modification of the Cysteines of VKORC1L1—
Differential modification of the cysteines of VKORC1L1 by
NEM and mPEG-MAL-5000 was performed as described pre-
viously (15, 37) with additional modifications. HA-tagged
VKORC1L1, or their cysteine mutants were transiently
expressed in FIXgla-PC/HEK293 cells in a 24-well plate. Cells
were cultured in complete medium containing 5 M KO to
facilitate the formation of the possible intermediate intra-mo-
lecular disulfide during KO reduction. Forty-eight hours post-
transfection, cells were washed twice in situ with PBS (pH 6.8)
and detached by pipetting. Cells were harvested by centrifuga-
tion, and cell pellets were resuspended in a lysis buffer (1%
Triton X-100, 2 mM PMSF, and 1 protease inhibitor mixture
in PBS) for cysteine modification. For mPEG-MAL-5000 mod-
ification of all the cysteines, cell pellets were resuspended in the
lysis buffer with 5 mM DTT. Samples were incubated on ice for
10 min, then freshly prepared mPEG-MAL-5000 solution was
added to a final concentration of 20 mM. The reactions were
incubated on ice for 1 h and stopped by adding DTT to a final
concentration of 50 mM.
For mPEG-MAL-5000 modification of the intra-molecular
disulfide, cell pellets were resuspended in a lysis buffer contain-
ing 50 mM NEM. Samples were incubated on ice for 1 h followed
by centrifuging at 14,000 rpm for 5 min. Supernatants were
transferred to Slide-A-Lyzer MINI dialysis units and dialyzed
against the lysis buffer to remove excess NEM. Intra-molecular
disulfide bonds were then reduced by adding freshly prepared
DTT to a final concentration of 5 mM, and the reaction mixture
was incubated on ice for 10 min. Freshly prepared mPEG-
MAL-5000 solution was added to the sample to a final concen-
tration of 20 mM and incubated on ice for 1 h. The reaction was
stopped by adding DTT to a final concentration of 50 mM, fol-
lowed by SDS loading buffer for SDS-PAGE, and Western blot
detection as described previously (15).
RESULTS
Determination of the Membrane Topology of VKORC1L1 in
HEK293 Cells—The membrane topology of VKORC1L1 was
predicted using ten different topology prediction programs
(38). Seven out of the ten programs predict four TMDs in
VKORC1L1. One program (SPOCTOPUS) predicts three
TMDs with a signal peptide. Two programs (PolyPhobius and
Phobius) predict three TMDs in VKORC1L1. All these pro-
grams predict that the C terminus of VKORC1L1 is located in
the cytoplasm, which is significant, since the reliability of topol-
ogy predictions is greatly increased if different prediction meth-
ods give the same prediction (39). The prediction program
TOPCONS, which is based on five different topology predic-
tion methods, performs better than other programs (40); like
most of the programs, TOPCONS predicts that VKORC1L1
is a 4-TMD membrane protein with both the N terminus and
the C terminus located in the cytoplasm. The predicted
membrane topology of VKORC1L1 agrees with that of
VKORC1 in the orientation of the last two TMDs, but differs
with regard to the location of the N terminus with respect to
the ER membrane (15, 16).
To experimentally determine the membrane topology of
VKORC1L1, we fused green fluorescence protein (GFP) to the
N or C terminus of VKORC1L1. We used the FPP assay to
probe the location of the two termini of VKORC1L1 molecules
in a single live HEK293 cell by fluorescence confocal micros-
copy. As a control, we fused GFP to the lumenal (N-) or the
cytoplasmic (C-) terminus of VKORC1 (Fig. 1A). These fusion
proteins were transiently expressed in HEK293 cells, and the
plasma membranes were selectively disrupted by digitonin, fol-
lowed by the addition of trypsin. Results show that when GFP is
located in the ER lumen of the control protein (GFP-VKORC1),
it is protected from trypsin digestion in digitonin-permeabi-
lized cells (Fig. 1B). However, the cytoplasmic terminal GFP
fusion of the control protein (VKORC1-GFP) is susceptible to
trypsin digestion.
Results in Fig. 1C shows that GFP fusions of either the N- or
C-terminal of VKORC1L1 are susceptible to protease digestion
indicating that both the N and C terminus of VKORC1L1 are
located in the cytoplasm. This result suggests that VKORC1L1
has an even number of TMD, which agrees with the above four-
TMD topology prediction. However, this result also supports a
two-TMD topology model for VKORC1L1. Because the pre-
Intra-molecular Electron Transfer in VKORC1L1
9398 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 289 • NUMBER 13 • MARCH 28, 2014
dicted TMD regions of VKORC1L1 and VKORC1 share high
sequence homology, and all four predicted TMDs in VKORC1
can function as authentic TMDs in both the in vitro (16) and the
in vivo (15) assay, we prefer the four-TMD rather than the two-
TMD topology model for VKORC1L1.
To confirm that the GFP fusions of VKORC1L1 used in the
FPP assay are properly folded and active, we used our recently
established cell-based activity assay to examine their ability to
convert KO to vitamin K to support vitamin K-dependent car-
boxylation (Fig. 2A) (35). We transiently expressed GFP fusions
of VKORC1L1 in HEK293 cells stably expressing the reporter
protein FIXgla-PC. The transfected cells were cultured with
KO and warfarin. Fig. 2B shows that VKORC1L1 fusions with
GFP, which is approximately twice the size of VKORC1L1,
retain 5070% of their activity compared with the wild-type
enzyme. This result demonstrates that the GFP-tagged
VKORC1L1 used in the FPP assay for the membrane topology
study has passed ER quality control and is enzymatically active.
We next compared VKORC1L1’s ability to reduce KO to
vitamin K with that of VKORC1 by transiently expressing the
two proteins in FIXgla-PC/HEK293 cells. Fig. 2C shows that,
like VKORC1, VKORC1L1 efficiently supports reporter-pro-
FIGURE 1. Localization of the N and C termini of VKORC1L1 in HEK293 cells by FPP assay. A, scheme of the FPP assay of GFP-tagged VKORC1 in a single cell
before and after digitonin and trypsin treatment. Lumenal (top) or cytoplasmic (bottom) terminus GFP-tagged VKORC1 was expressed in HEK293 cells.
Digitonin treatment permeabilizes the cell membrane while leaving the ER membrane intact. Only the cytoplasmic terminus-tagged GFP fusion is susceptible
to protease (trypsin) treatment (bottom). B, FPP assay of VKORC1 in HEK293 cells. GFP-tagged VKORC1 fusions were transiently expressed in HEK293 cells.
Forty-eight hours post-transfection, cells were selectively permeabilized with 0.1 mM digitonin. Then trypsin was added, and images were collected at the
indicated time intervals. C, FPP assay of VKORC1L1 in HEK 293 cells as described above.
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tein carboxylation using KO as the substrate, which agrees with
our recent study (33). This result suggests that, in vivo, both
VKORC1L1 and VKORC1 are able to efficiently convert KO to
vitamin K to support vitamin K-dependent carboxylation.
The Conserved Loop Cysteines in VKORC1L1 Are Essential
for Its Function—We previously reported that the conserved
loop cysteines (Cys-43 and Cys-51) in VKORC1 are located in
the cytoplasm and are not required for VKORC1 function (12,
15, 41). In contrast to VKORC1, the conserved loop cysteines of
VKORC1L1 (Cys-50 and Cys-58) are located in the ER lumen,
the same side of the ER membrane as the CXXC active site. To
examine whether the loop cysteines in VKORC1L1 are essential
for its function, we mutated these two loop cysteines to serine
either individually (C50S or C58S) or together (C50S/C58S).
We then measured their activities using our cell-based assay.
Our results show that mutating the loop cysteines, either indi-
FIGURE 2. Cell-based in vivo KO reductase activity assay. A, scheme of the cell-based in vivo KO reductase activity assay. HEK293 cells stably expressing the
chimeric reporter protein FIXgla-PC were used for in vivo activity assay. Warfarin was used to inhibit the endogenous KO reductase activity. Exogenously
expressed warfarin-resistant VKORC1 or VKORC1L1 converts KO to vitamin K. Vitamin K is further reduced to KH2 by the endogenous warfarin-resistant vitamin
K reductase (antidotal enzyme) for reporter protein carboxylation. Carboxylated FIXgla-PC secreted in the cell culture medium was measured by ELISA to
evaluate the functionality of the exogenously expressed VKORC1 or VKORC1L1. B, cell-based in vivo KO reductase activity of VKORC1L1 and its GFP fusions used
in the FPP assay. Warfarin-resistant VKORC1L1 (Y146F) and its GFP fusions were transiently expressed in FIXgla-PC/HEK293 cells. Transfected cells were cultured
in complete medium containing 5 M KO and 2 M warfarin for 48 h. The concentration of carboxylated FIXgla-PC in the cell culture medium was measured by
ELISA and normalized by the luciferase activity, as described under “Experimental Procedures.” C, KO reductase activity of VKORC1L1 and VKORC1. Warfarin-
resistant VKORC1 (Y139F) or VKORC1L1 (Y146F) was transiently expressed in FIXgla-PC/HEK293 cells, and the enzymatic activity was determined as described
above. Data are presented as mean  S.D. (n  3).
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vidually or together, abolished VKORC1L1 activity (Fig. 3A).
This suggests that, unlike VKORC1, the conserved loop cys-
teines (Cys-50 and Cys-58) are essential for VKORC1L1
activity.
In bacterial VKORHs, the conserved loop cysteines are
involved in active site regeneration by an intra-molecular elec-
tron transfer pathway. Mutating either of the loop cysteines
diminished enzyme activity in an E. coli cell-based assay (25);
however, the same cysteine mutants are active in an in vitro
assay where the active site is directly reduced with DTT (26).
Since VKORC1L1 and bacterial VKORHs have similar mem-
brane topologies (25), one would expect that they might have a
similar mechanism of function. To test this hypothesis, we
expressed VKORC1L1 and its loop cysteine mutants in insect
cells (Sf9). The enzymatic activity of reducing KO to vitamin K
was measured by an in vitro assay using DTT as the reductant.
Our results show that the VKORC1L1 C50S mutant has 40%
activity compared with the wild-type enzyme (Fig. 3B). Impor-
tantly, C58S and C50S/C58S mutants retain 80% activity of
the wild-type VKORC1L1. These results are similar to that of
VKORH in bacteria (26), suggesting that the intra-molecular
electron transfer pathway for active site regeneration by the
loop cysteines applies to VKORC1L1.
Capture of the Intermediate Disulfide Bond between the Loop
and the Active Site Cysteines of VKORC1L1—To further con-
firm the above conclusion and to identify the intra-molecular
disulfide linkage between the loop and the active site cysteine,
we used differential chemical modification of free cysteines and
disulfide-linked cysteines in VKORC1L1. For detection pur-
poses, we fused a HA tag to the C terminus of VKORC1L1 and
its cysteine mutants. We transiently expressed HA-tagged
VKORC1L1 or its variants in FIXgla-PC/HEK293 cells and cul-
tured the cells with KO to facilitate the formation of the possi-
ble intermediate disulfide during KO reduction. Transfected
cells were lysed and free cysteines were blocked by N-ethylma-
leimide (NEM) modification to trap the intermediate disulfide.
Protein-disulfide bonds were then reduced by DTT and labeled
by mPEG-MAL-5000. The procedure is illustrated in the
scheme shown in Fig. 4A. Modification of each cysteine by
mPEG-MAL-5000 is expected to increase the apparent molec-
ular mass of the parent protein by 10 kDa (37), making it
easily separated by SDS-PAGE and visualized by Western blot
analysis.
Fig. 4B shows the results of differential modification of
VKORC1L1 and its cysteine mutants. As the control, we
reduced all the possible disulfide linkages in VKORC1L1 and
labeled all the free cysteines directly by mPEG-MAL-5000
without NEM blocking. Our result shows that five PEG-labeled
protein bands with higher molecular weight are observed, indi-
cating that all five cysteines in VKORC1L1 can be modified by
PEG (Fig. 4B, lane 2). The most populated forms of VKORC1L1
have five and one cysteines modified by PEG. It should be noted
that except for the 5-PEG modified protein band, all other
bands represent the number of cysteines modified by PEG; it
does not necessarily mean modification of the same cysteines.
When the free cysteines of VKORC1L1 are blocked by NEM
before DTT reduction and PEG modification, the most domi-
nant population of VKORC1L1 has two cysteines labeled by
PEG (Fig. 4B, lane 3) indicating that two cysteines are protected
from NEM blocking and can be reduced by DTT and labeled by
PEG. This result suggests the existence of a disulfide bond
within VKORC1L1. In addition, different from the control sam-
ple (Fig. 4B, lane 2), a non-PEG-labeled protein band was
observed due to NEM blocking of the free cysteines. Unexpect-
edly, we also observed the 3- and 4-PEG modified protein
bands. This result suggests that either there are more than one
disulfide bonds in VKORC1L1 during KO reduction or NEM
did not efficiently block all the free cysteines before PEG
modification.
FIGURE 3. In vivo (A) and in vitro (B) activity assays of the loop cysteine mutants of VKORC1 and VKORC1L1. A, cell-based in vivo KO reductase activity
assay. Loop cysteine mutants of VKORC1L1 (black bars) or VKORC1 (gray bars) were transiently expressed in FIXgla-PC/HEK293 cells, and the enzymatic activity
was determined as described in the legend for Fig. 2. B, DTT-driven in vitro KO reductase activity assay. VKORC1L1 and its loop cysteine mutants were expressed
in insect cells (Sf9). The enzymatic activity of converting KO to vitamin K of microsomes containing these mutants was measured by DTT-driven in vitro activity
assay and normalized by the total microsomal protein concentration (black bars). The gray bars are the in vitro activities of VKORC1 and its loop cysteine mutants
from our previous study (12). Data are presented as mean  S.D. (n  3).
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Fig. 4C elucidates the possible disulfide linkage in
VKORC1L1 during KO reduction. When KO is reduced to
vitamin K, the active site cysteines are oxidized to a disulfide
(Fig. 4C, scheme 1). Partial reduction of the active site disulfide
by a loop cysteine results in an intermediate disulfide between
the loop and the active site cysteines (Fig. 4C, scheme 2). Full
reduction of the active site results in the oxidation of the loop
cysteines to a disulfide (Fig. 4C, scheme 3). When the loop disul-
fide is partially reduced by the reductant of VKORC1L1, it
forms an intermediate disulfide between the loop cysteine and
the cysteine of the reductant (Fig. 4C, scheme 4). The active site
cysteines of VKORC1L1 can form a disulfide by KO reduction
before the loop disulfide is fully reduced (Fig. 4C, scheme 5). If
the rate of reduction for the loop disulfide is significantly slower
than that of oxidation of the active site cysteines, both the loop
and active site cysteines may be disulfide linked (Fig. 4C, scheme
6). Of all these possible disulfide linkages, most of them contain
one intra-molecular disulfide. Differential modification of any
of these intermediates would result in a 2-PEG modification of
VKORC1L1, which agrees with the most intense 2-PEG-labeled
protein band (Fig. 4B, lane 3). In the case in which VKORC1L1’s
active site cysteines are oxidized and its loop cysteines are par-
tially reduced (Fig. 4C, scheme 5), three cysteines would be pro-
tected from NEM blocking. This species may be represented by
the 3-PEG-labeled protein band observed in Fig. 4B, lane 3.
However, the source of VKORC1L1 with 4-PEG modification is
not clear (Fig. 4B, lane 3). It seems unlikely that this is due to the
PEG labeling of four cysteines protected by two disulfide bonds
(Fig. 4C, scheme 6). If this were the case, VKORC1L1 would not
be an efficient enzyme for KO reduction due to the slow rate of
active site regeneration which disagrees with the result of the
activity assay (Fig. 2C). In addition, it also seems unlikely that
the 4-PEG-labeled protein band is due to the inefficient block-
ing of free cysteine by NEM, as we observed a similar result
when we increased NEM concentration to 100 mM in the block-
ing reaction (data not shown). Moreover, if a cysteine residue is
FIGURE 4. Identification of the intermediate disulfide linkage between the loop cysteine and the active site cysteine in VKORC1L1. A, scheme of
differential modification of protein free cysteines and intra-molecular disulfide. Free cysteines in the protein are blocked by NEM modification. Intra-molecular
disulfide is reduced by DTT and then labeled by mPEG-MAL-5000. Modification of each cysteine by PEG-MAL-5000 increases the apparent molecular weight of
the parent protein by 10 kDa, which can be separated by SDS-PAGE. B, capture of the intermediate-disulfide of VKORC1L1. HA-tagged VKORC1L1 or its
cysteine mutants was transiently expressed in FIXgla-PC/HEK293 cells. Forty-eight hours post-transfection, cells were lysed with Triton X-100 before NEM or
mPEG-MAL modification. As the control, cell lysate that express wild-type VKORC1L1 was reduced by DTT and directly labeled with mPEG-MAL-5000 (lane 1).
All other samples were first modified by NEM and excess NEM was removed by dialysis. Intra-molecular disulfide(s) was reduced by DTT and then labeled with
mPEG-MAL-5000. C, scheme of the possible disulfide linkage in VKORC1L1. The disulfide bond is indicated by a dashed line. Scheme 1, disulfide-linked active site
cysteines; scheme 2, intermediate disulfide between the loop cysteine and the active site cysteine; scheme 3, disulfide-linked loop cysteines with reduced active
site; scheme 4, partially reduced loop disulfide with reduced active site (VKORC1L1’s reductant is depicted as a gray circle with the letter R); scheme 5, partially
reduced loop disulfide with oxidized active site; scheme 6, disulfide-linked loop cysteines and active site cysteines.
Intra-molecular Electron Transfer in VKORC1L1
9402 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 289 • NUMBER 13 • MARCH 28, 2014
not accessible to NEM modification at a higher concentration
(50 mM), theoretically, it should not be accessible to a maleim-
ide derivative with a bulky side chain (PEG) at a low concentra-
tion (20 mM).
To identify the disulfide linkage between the loop and the
active site cysteines, we first mutated the loop cysteines, Cys-50
and Cys-58, individually to serine and repeated the above
differential modification experiment. PEG modification of
VKORC1L1 C50S mutant shows a pattern similar to that of the
wild-type enzyme (Fig. 4B, lane 4), suggesting that mutating
Cys-50 does not affect the number of cysteines protected from
NEM blocking by disulfide bond. However, mutating Cys-58
abolishes PEG modification of two cysteines in VKORC1L1, as
evidenced by the disappearance of two PEG-labeled protein
bands (Fig. 4B, lane 5). Moreover, compared with the wild-type
enzyme (Fig. 4B, lane 3), the C58S mutation significantly
decreased the population of the 2-PEG-labeled protein band
with a dramatic increase in the non-PEG-labeled protein band
due to NEM blocking of free cysteines. This result suggests that
mutating Cys-58 decreased the amount of disulfide formation
and increased the free cysteines in VKORC1L1. The 2-PEG-
labeled protein band in the C58S mutant could result from PEG
modification of the disulfide-linked active site cysteines (Fig.
4C, scheme 1). These results together suggest that Cys-58 is the
catalytic cysteine that forms a disulfide with the active site cys-
teine, and that Cys-50 serves as the canonical resolving cysteine
that reduces the intermediate disulfide to release the active site
cysteines as the fully reduced form (42).
To further identify the active site cysteine that forms disul-
fide with Cys-58, we mutated Cys-139 and Cys-142 individually
and repeated the NEM and mPEG-MAL-5000 differential
modification experiment. To stabilize the intermediate disul-
fide bond between the loop and the active site cysteines (Fig. 4C,
scheme 2), we also mutated the resolving cysteine, Cys-50, to
serine in the C139S and C142S VKORC1L1 mutants. There-
fore, the only possible disulfide linkage of the electron transfer
chain in these two mutants is either between the loop (Cys-58)
and the active site cysteines (Fig. 4C, scheme 2) or the loop and
VKORC1L1’s reductant cysteines (Fig. 4C, scheme 4), with a
maximum number of two cysteines being protected by NEM
and labeled by PEG. Our result shows that mutating Cys-139
(C50S/C139S) abolishes three PEG-labeled protein bands (Fig.
4B, lane 6) compared with the C50S mutant (Fig. 4B, lane 4). In
addition, the intensity of the non-PEG-labeled protein band
increased significantly. This result suggests that Cys-139 is
involved in disulfide formation with the loop cysteine, Cys-58.
This result is further supported by the result of differential
modification of the C50S/C142S mutant where two cysteines
can be labeled by PEG (Fig. 4B, lane 7), and the only possible
disulfide linkage that protects two cysteines from NEM block-
ing in C50S/C142S mutant is the disulfide between Cys-58 and
Cys-139 (Fig. 4C, scheme 2).
The Overall Structure Rather Than the Specific Loop
Sequence Distinguishes the Mechanism of Action between
VKORC1 and VKORC1L1—VKORC1L1 and VKORC1 share
50% amino acid sequence identity, but results from this study
show that these two proteins have different membrane topolo-
gies and reaction mechanisms. VKORC1L1 requires the con-
served loop cysteines to reduce the active site disulfide by an
intra-molecular electron transfer pathway, which is not the
case for VKORC1. To examine whether the specific loop
sequence or the active site sequence of VKORC1L1 are unique
for the intra-molecule electron transfer, we first replaced the
active site sequence of VKORC1L1 with that of VKORC1
(boxed residues in Fig. 5A). The resulting chimeric protein was
designated VKORC1L1 (Fig. 5B). In vivo cell-based activity
assays show that the chimeric protein of VKORC1L1 that con-
tains VKORC1’s active site is fully active (1.6-fold more active
than wild-type VKORC1L1) (Fig. 5C). To explore whether
VKORC1’s active site in the chimeric protein VKORC1L1 is
regenerated by the loop cysteines of VKORC1L1 via the intra-
molecular electron pathway or directly reduced by an unknown
physiological reductant as in VKORC1 (15, 41), we mutated the
loop cysteines of VKORC1L1 and examined their effect on the
enzymatic activity. Fig. 5D shows that mutating either or both
of the loop cysteines abolished the enzymatic activity of
VKORC1L1. These results suggest that the loop cysteines of
VKORC1L1 are required for the regeneration of VKORC1’s
active site in the chimeric protein.
Next, we examined whether the specific loop sequence
contributes to the different reaction mechanisms between
VKORC1L1 and VKORC1. Fig. 6A shows that amino acid res-
idues around the second loop cysteine are substantially differ-
ent between VKORC1 and VKORC1L1. We therefore replaced
the loop region of VKORC1L1 with that of VKORC1 (boxed
residues in Fig. 6A). The resulting chimeric protein was desig-
nated VKORC1L1 (Fig. 6B). The results of our cell-based in
vivo assay show that the activity of VKORC1L1 is similar to the
wild-type enzyme (Fig. 6C). Mutating the loop cysteines of this
chimeric VKORC1L1 results in the loss of enzymatic activity
(Fig. 6D), suggesting that the loop cysteines of VKORC1 are
essential for the regeneration of VKORC1L1’s active site in the
chimeric protein. Importantly, these loop cysteines are not
required for VKORC1’s active site regeneration (15). These
results together suggest that the overall structure of
VKORC1L1, rather than specific sequences within the loop
region or the active site region, is responsible for the different
reaction mechanisms of VKORC1L1 and VKORC1.
DISCUSSION
Characterization of the human VKORC1 and its bacterial
homologues yielded important structure-function information
about this family of enzymes (15, 24, 26). Unlike its bacterial
homologues, human VKORC1 is a three-TMD membrane pro-
tein, with its N terminus located in the ER lumen and its C
terminus in the cytoplasm (15). The biological function of
VKORC1 is to reduce KO to vitamin K for vitamin K-depen-
dent carboxylation, and its enzymatic activity is sensitive to
warfarin inhibition (33, 35). VKORC1L1, a paralogous enzyme
of VKORC1, shares 50% protein sequence identity with
VKORC1 (1). However, the physiological function and the
structure of VKORC1L1 are not yet clear.
The results presented in this study (Fig. 2C), which agree
with our previous results (33), indicate that VKORC1L1, like
VKORC1, can efficiently reduce KO, as evidenced by its ability
to support vitamin K-dependent carboxylation in HEK293
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cells. This contrasts with the results of Westhofen et al., which
indicated that VKORC1L1 reduces KO 18,054-fold slower than
does VKORC1 (31). Based on their results, these authors
hypothesized that the primary physiological function of
VKORC1L1 is to reduce vitamin K to KH2. It should be noted,
however, that the conclusion of Westhofen et al. is based on the
comparison of the enzymatic activity of VKORC1L1 in crude
cell lysate in the presence of detergent (31) to that of purified
VKORC1 reconstituted in intact membranes (43). Addition-
ally, without knowing the expression level of VKORC1L1, they
FIGURE 5. VKORC1’s activity site can be reduced by the loop cysteines of VKORC1L1. A, sequence alignment of VKORC1 and VKORC1L1 near the active site
region. Completely conserved residues are indicated by asterisks. Conserved active site cysteines are indicated by arrows. The warfarin binding motif (TYA/TYV)
is underlined. Transmembrane regions are highlighted in gray. Active site sequence replacement is indicated by a box. B, scheme of VKORC1L1 molecule with
its active site region replaced by that of VKORC1 (VKORC1L1). Dashed lines and the black cylinder with white dots indicate sequences from VKORC1. C, cell-based
in vivo activity assay of VKORC1L1 and VKORC1L1. D, cell-based in vivo activity assay of loop cysteine mutants of VKORC1L1. Enzymatic activity was deter-
mined as described in the legend for Fig. 2. Data are presented as mean  S.D. (n  3).
FIGURE 6. VKORC1’s loop cysteines can transfer electrons to the active site of VKORC1L1. A, sequence alignment of VKORC1 and VKORC1L1 near the conserved
loop cysteine region. Completely conserved residues are indicated by asterisks. Conserved loop cysteines are highlighted in gray and indicated by arrows. Loop
sequence replacement is indicated by a box. B, scheme of VKORC1L1 molecule with its conserved cysteine containing loop region replaced by that of VKORC1
(VKORC1L1). Dashed lines indicate sequences from VKORC1. C, cell-based in vivo activity assay of VKORC1L1 and VKORC1L1. D, cell-based in vivo activity of loop
cysteine mutants of VKORC1L1. Enzymatic activity was determined as described in the legend for Fig. 2. Data are presented as mean  S.D. (n  3).
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calculated their specific enzymatic activity of VKORC1L1
based upon total proteins in the whole-cell lysates (31). Inexpli-
cably, they compared this activity with the specific activity of
purified VKORC1 calculated from a published turnover num-
ber (43). On the other hand, results from the same study show
that under the same conditions, VKORC1L1 and VKORC1
have a similar ability to reduce KO to vitamin K (31). Therefore,
it is premature to conclude that the primary physiological func-
tion of VKORC1L1 is to reduce vitamin K to KH2.
Recently, Hammed et al. reported that VKORC1L1 might
rescue VKORC1 function in extrahepatic tissues during antico-
agulation therapy (30). This hypothesis is based on their in vitro
kinetic results, which suggest that VKORC1L1 is 50-fold more
resistant to warfarin inhibition than VKORC1. Our in vivo results,
however, show that VKORC1L1 and VKORC1 have similar war-
farin resistance (33). The experiments of Hammed et al. were care-
fully done; however, there are at least two possibilities to explain
the discrepancy. First, Hammed et al. used DTT-driven in vitro
activity assay in their study, while we used our cell-based in vivo
activity assay, in which the enzymes function in their native milieu.
It has been reported that the DTT-driven in vitro assay is a mis-
leading for the study of warfarin resistance (44). In addition, DTT
directly reduces the active site disulfide in the in vitro assay, which
bypasses the function of the loop cysteines; as shown in the present
study, these cysteines are essential for the function of VKORC1L1
but not for that of VKORC1. Therefore, until all of the compo-
nents required for VKORC1’s and VKORC1L1’s functions are
known and can be reassembled into a stable functional membrane
complex in vitro, it is problematic to infer too much functional
significance from in vitro studies. Secondly, Hammed et al.
expressed VKORC1L1 and VKORC1 in yeast (Pichia pastoris),
while we expressed these enzymes in mammalian cells (HEK293).
It has been reported that VKORC1L1 and VKORC1 expressed in
HEK293 cells only exhibit a 1.8-fold difference in warfarin sensi-
tivity (31) even in the in vitro activity assay, which agrees with our
previous result (33). Thus, it seems unlikely that VKORC1L1 func-
tions as the “antidotal” enzyme that allows carboxylation of pro-
teins in the presence of warfarin in the native milieu. Therefore,
the physiological function of VKORC1L1 remains unknown.
Our topology study shows that, unlike VKORC1,
VKORC1L1 is a 4-TMD membrane protein with both termini
located in the cytoplasm. The main topological difference
between VKORC1L1 and VKORC1 is the orientation of the
first TMD in the ER membrane. VKORC1’s TMD1 has the ori-
entation of Nout-Cin, while VKORC1L1’s is Nin-Cout. The ori-
entation of TMD is primarily determined by the charged resi-
dues flanking the hydrophobic core, the “positive-inside rule”
(45, 46); that is, positively charged residues are more abundant
on the cytoplasmic side (inside) than the lumenal/periplasmic
side (outside) of the membrane. According to the rules laid out
by Hartmann et al. (46), the net charge difference between the
C- and N-terminal flanking the TMD1 of VKORC1 is 1.5. By
contrast, the net charge difference of VKORC1L1’s TMD1 is
	3.0. The two proteins thus have a very different distribution of
charged residues flanking TMD1; according to the “positive
inside rule”, the TMD1 of VKORC1 and that of VKORC1L1
should thus have different orientations. This agrees with the
results from our experimentally-determined topology models.
Another topological difference between VKORC1L1 and
VKORC1 is the location of the conserved loop cysteines in rela-
tion to the ER membrane. In VKORC1L1, the conserved loop
cysteines (Cys-50 and Cys-58) are located in the ER lumen,
while those of VKORC1 are located in the cytoplasm. We have
shown previously, by both in vitro and in vivo studies, that
VKORC1’s loop cysteines, whether located in the cytoplasm or
ER lumen, are not required for its function (12, 15, 41). Here,
however, we find that VKORC1L1’s loop cysteines are essen-
tial for its activity (Fig. 3). Results from replacement of
VKORC1L1’s active site sequence or loop sequence with that
of VKORC1 (Figs. 5 and 6) suggest that it is VKORC1L1’s
overall structure that uniquely allows for active site regener-
ation by the loop cysteines.
Our results from intermediate disulfide-trapping experiments
suggest the following intra-molecular electron transfer pathway
for VKORC1L1’s active site regeneration. The second loop cys-
teine (Cys-58) carries out a nucleophilic attack on the active-site
disulfide bond; this leads to the reduction of Cys-142 and the for-
mation of an intermediate disulfide bond between Cys-58 and
Cys-139. Then, the first loop cysteine (Cys-50) serves as the canon-
ical resolving cysteine that attacks the intermediate disulfide (42),
resulting in the reduction of active-site cysteines and the oxidiza-
tion of the loop cysteines (disulfide-bonded). These reactions
transfer two electrons from the loop cysteines to the active site.
The oxidized loop cysteines will then need to be reduced by an
as-yet-unidentified reductant for the enzyme to be recycled. This
electron flow in VKORC1L1, but not in VKORC1, is similar to that
of DsbB and the bacterial VKORH (47).
Our studies suggest that the structure and the active site
regeneration mechanism of human VKORC1L1 are similar to
that of bacterial VKORHs but different from that of human
VKORC1. This suggests that VKORC1L1 evolved earlier than
VKORC1. Whether VKORC1 in the lower species functions as
KO reductase or is involved in disulfide-bond formation is still
an open question. However, it is clear that VKORC1L1 in
higher species lost its function as KO reductase under physio-
logical conditions (33, 34).
In conclusion, we studied the membrane topology and the
function of VKORC1L1 in mammalian cells. Our results sug-
gest that, unlike VKORC1, VKORC1L1 is a four-TMD protein
with its conserved loop cysteines located in the ER lumen. Cell-
based in vivo activity assay shows that VKORC1L1 can support
vitamin K-dependent carboxylation as efficiently as VKORC1.
The conserved loop cysteines of VKORC1L1, but not VKORC1,
are involved in active site regeneration through an intra-molec-
ular pathway. The different structures and reaction mecha-
nisms of VKORC1L1 and VKORC1 may imply that these two
enzymes have different physiological functions.
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